Fighting Counterfeit Medicines in Europe: The Effect on Access to Medicines | Zendy

Maarten Van Baelen | Zendy; Pieter Dylst | Zendy; Catarina Lopes Pereira | Zendy; Johan Verhaeghe | Zendy; Koen Nauwelaerts | Zendy; Susie Lyddon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fighting Counterfeit Medicines in Europe: The Effect on Access to Medicines

Author(s) -

Maarten Van Baelen,

Pieter Dylst,

Catarina Lopes Pereira,

Johan Verhaeghe,

Koen Nauwelaerts,

Susie Lyddon

Publication year - 2017

Publication title -

medicine access point of care

Language(s) - English

Resource type - Journals

ISSN - 2399-2026

DOI - 10.5301/maapoc.0000010

Subject(s) - directive , counterfeit , counterfeit drugs , business , obstacle , risk analysis (engineering) , internet privacy , computer security , medicine , computer science , political science , law , programming language

The implementation of the Falsified Medicines Directive, and its Delegated Regulation with detailed specifications of safety features, will provide an additional obstacle for counterfeiters. The implementation of the Directive aims to prevent falsified medicines from reaching patients, and is in the interest of public health. However, the financial burden for manufacturers to implement these additional safety features, as well as the repository system that will allow the verification of authenticity of individual packs of medicine, may threaten the availability of medicines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research